MX2019008535A - Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. - Google Patents
Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.Info
- Publication number
- MX2019008535A MX2019008535A MX2019008535A MX2019008535A MX2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A
- Authority
- MX
- Mexico
- Prior art keywords
- pparï
- huntington
- disease
- treatment
- agonist
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Metodos de tratamiento de la enfermedad de Huntington o de los sintomas de la misma con agonistas de PPAR? y, en particular, el compuesto de formula (I) conocido tambien como INT131: (ver fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008535A true MX2019008535A (es) | 2019-12-02 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008535A MX2019008535A (es) | 2017-01-18 | 2018-01-18 | Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (es) |
| EP (1) | EP3570841A4 (es) |
| JP (1) | JP2020505448A (es) |
| KR (1) | KR20190122664A (es) |
| CN (1) | CN110461330A (es) |
| AU (1) | AU2018210165A1 (es) |
| BR (1) | BR112019014529A2 (es) |
| CA (1) | CA3050104A1 (es) |
| EA (1) | EA201991716A1 (es) |
| IL (1) | IL268008A (es) |
| MX (1) | MX2019008535A (es) |
| SG (1) | SG11201906644YA (es) |
| WO (1) | WO2018136635A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180006881A (ko) | 2015-03-09 | 2018-01-19 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| WO2006044381A2 (en) * | 2004-10-13 | 2006-04-27 | University Of Connecticut | Cannabinergic lipid ligands |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| ES2739976T3 (es) * | 2009-07-01 | 2020-02-05 | Jds Therapeutics Llc | Complejos de cromo como potenciadores de transportadores de glucosa cerebral |
| US20150174118A1 (en) * | 2013-12-20 | 2015-06-25 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod to delay huntington's disease progression |
-
2018
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3570841A4 (en) | 2020-08-19 |
| EP3570841A1 (en) | 2019-11-27 |
| US20190350918A1 (en) | 2019-11-21 |
| CN110461330A (zh) | 2019-11-15 |
| IL268008A (en) | 2019-09-26 |
| JP2020505448A (ja) | 2020-02-20 |
| EA201991716A1 (ru) | 2020-02-04 |
| WO2018136635A1 (en) | 2018-07-26 |
| SG11201906644YA (en) | 2019-08-27 |
| AU2018210165A1 (en) | 2019-08-01 |
| KR20190122664A (ko) | 2019-10-30 |
| CA3050104A1 (en) | 2018-07-26 |
| BR112019014529A2 (pt) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| NZ763098A (en) | Thiazolopyridine derivatives as gpr119 agonists | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| SG10201903823QA (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| MX2009009207A (es) | Metodos y composiciones para normalizar las secreciones de glandulas meibomianas. | |
| EA201591743A1 (ru) | СТИМУЛЯТОРЫ sGC | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
| CA3073829A1 (en) | Methods and compositions for detecting and treating endometriosis | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| MX366765B (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| MX2020012800A (es) | Cannabinoides y usos de los mismos. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2019001979A (es) | Agonista de ppar? para el tratamiento de neoplasias hematicas. | |
| MX2019011867A (es) | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. | |
| MX2019008535A (es) | Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. |